For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211213:nRSM3557Va&default-theme=true
RNS Number : 3557V Byotrol PLC 13 December 2021
Byotrol plc ("Byotrol" or the "Company")
Directorate Change
Byotrol plc (AIM: BYOT), the infection prevention technology company, is
pleased to announce the appointment of Chris Sedwell as CFO of the Company.
Chris joins the Board of Directors with immediate effect.
Nic Hellyer, part-time CFO since May 2019 has now formally left the Company,
but will continue to be available to assist in an orderly handover process.
Chris is ACA trained and an ICAEW fellow. He was most recently Portfolio
Finance Director of FD & CFO Centre, working with various SMEs to provide
finance consultancy. For the preceding six years he was Finance Director of
ConvaTec Limited, a FTSE250 listed medical products and technologies business.
Prior to this, he was Head of Finance & Administration at Iceland
International, a part of the UK supermarket chain Iceland Foods Group.
At the date of this announcement, Mr Sedwell does not have any beneficial
interest in the ordinary shares of the Company.
Commenting on the appointment, John Langlands, Chairman of Byotrol plc, said:
"We are very pleased to welcome Chris Sedwell to the Board of Byotrol. He
has a wealth of highly relevant industrial and healthcare experience, from
listed company to SME. We are convinced that he will be a very important
asset to the Company as we continue to grow and develop.
We thank Nic Hellyer for his service to the Company and wish him every success
for the future."
Enquiries:
Byotrol Plc
John Langlands - Chairman +44 (0)1925 742 000
David Traynor - Chief Executive
finnCap (Nominated Adviser and Broker) +44 (0)20 7220 0500
Geoff Nash/Kate Bannatyne - Corporate Finance
Richard Chambers - ECM
Flagstaff Strategic and Investor Communications +44 (0)20 7129 1474
Tim Thompson/Andrea Seymour/Fergus Mellon byotrol@flagstaffcomms.com (mailto:byotrol@flagstaffcomms.com)
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and
control company, operating globally in the Healthcare, Industrial, Food and
Consumer sectors, providing low toxicity products with a broad-based and
targeted efficacy across all microbial classes; bacteria, viruses (including
coronavirus), fungi, moulds, mycobacteria and algae.
Byotrol's products can be used stand-alone or as ingredients within existing
products, where they can significantly improve their performance, especially
in personal hygiene, domestic and industrial disinfection, odour control, food
production and food management.
Byotrol develops and commercialises technologies that create easier, safer and
cleaner lives for everyone.
For more information, please go to byotrol.co.uk
Christopher John Sedwell, aged 45, is, or has been within the last five years,
a director or partner in the following companies and partnerships:
Current directorships and partnerships Previous directorships and partnerships held within the last five years
Sedwell Consulting Limited ConvaTec Limited
Unomedical Holdings Limited
ConvaTec Accessories Limited
Unomedical Limited
Amcare Limited
Alpha-Med (Medical & Surgical) Limited
SureCalm Healthcare Limited
SureCalm Pharmacy Limited
Surecalm Healthcare Holdings Limited
B.C.A Direct Limited
Resus Positive Limited
Akers & Dickinson Limited
Novacare UK Limited
Unomedical Developments Limited
Unoplast (UK) Limited
Steriseal Limited
Pharma-Plast Limited
Farnhurst Medical Limited
ConvaTec Speciality Fibres Limited
Nottingham Medical Equipment Limited
Needle Industries (Sheffield) Limited
Lance Blades Limited
M.S.B Limited
Rotax Razor Company Limited
Arthur Wood Limited
Allied Medical Services (UK) Limited
Bradgate-Unitech Limited
Shrimpton & Fletcher Limited
There are no further disclosures regarding Chris Sedwell pursuant to Rule 17
and Schedule 2(g) of the AIM Rules for Companies.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOAEAXAAFAAFFFA